Pancreatic cancer metastasis: Are we being pre-EMTed?

Srustidhar Das, Surinder Kumar Batra

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Pancreatic cancer, often considered a metastatic disease at the time of clinical diagnosis due to lack of any reliable early diagnostic marker(s), is refractory to conventional chemo-and radiotherapy and has a dismal 5-year survival rate of only 6%. Although surgical removal of the primary tumor is considered to be curative, the 5-year survival rate is no more than 20% even in patients with clear resection margins (R0). The recurrence of local and metastatic disease (primarily liver metastasis) post resection is considered to be the leading cause of mortality in these patients. In addition, instances of metastatic disease without any local recurrence post resection have also been observed. Cancer metastasis is the primary cause of mortality in cancer patients and is classically viewed as a late event during the progression of the disease, which is supp orted by the genetic studies used to understand the evolution of pancreatic cancer. However, this view has recently been challenged by studies using mathematical modeling and genetically labeled mouse models of pancreatic cancer to understand the dynamics of tumor cell dissemination and epithelial to mesenchymal transition (EMT) of tumor cells well before the primary tumor is formed. Given that EMT is a hallmark process that initiates the metastatic seeding of cancer cells and the dismal prognosis of pancreatic cancer patients even after efficient removal of the primary tumor (99.9%), an early dissemination hypothesis of cancer cells cannot be undermined. In this review, we will discuss the current views regarding pancreatic cancer metastasis with particular emphasis on the epithelial to mesenchymal transition, its influence on the selection of patients for surgical resection and the therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)1249-1255
Number of pages7
JournalCurrent Pharmaceutical Design
Volume21
Issue number10
DOIs
StatePublished - Jan 1 2015

Fingerprint

Pancreatic Neoplasms
Neoplasm Metastasis
Neoplasms
Epithelial-Mesenchymal Transition
Survival Rate
Recurrence
Mortality
Patient Selection
Disease Progression
Liver Diseases
Radiotherapy

Keywords

  • Epithelial to mesenchymal transition (EMT)
  • Linear progression model
  • Metastasis
  • Pancreatic cancer
  • Parallel progression model

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Pancreatic cancer metastasis : Are we being pre-EMTed? / Das, Srustidhar; Batra, Surinder Kumar.

In: Current Pharmaceutical Design, Vol. 21, No. 10, 01.01.2015, p. 1249-1255.

Research output: Contribution to journalArticle

@article{e2854c32613040fc8e5c1983fcab6dd4,
title = "Pancreatic cancer metastasis: Are we being pre-EMTed?",
abstract = "Pancreatic cancer, often considered a metastatic disease at the time of clinical diagnosis due to lack of any reliable early diagnostic marker(s), is refractory to conventional chemo-and radiotherapy and has a dismal 5-year survival rate of only 6{\%}. Although surgical removal of the primary tumor is considered to be curative, the 5-year survival rate is no more than 20{\%} even in patients with clear resection margins (R0). The recurrence of local and metastatic disease (primarily liver metastasis) post resection is considered to be the leading cause of mortality in these patients. In addition, instances of metastatic disease without any local recurrence post resection have also been observed. Cancer metastasis is the primary cause of mortality in cancer patients and is classically viewed as a late event during the progression of the disease, which is supp orted by the genetic studies used to understand the evolution of pancreatic cancer. However, this view has recently been challenged by studies using mathematical modeling and genetically labeled mouse models of pancreatic cancer to understand the dynamics of tumor cell dissemination and epithelial to mesenchymal transition (EMT) of tumor cells well before the primary tumor is formed. Given that EMT is a hallmark process that initiates the metastatic seeding of cancer cells and the dismal prognosis of pancreatic cancer patients even after efficient removal of the primary tumor (99.9{\%}), an early dissemination hypothesis of cancer cells cannot be undermined. In this review, we will discuss the current views regarding pancreatic cancer metastasis with particular emphasis on the epithelial to mesenchymal transition, its influence on the selection of patients for surgical resection and the therapeutic intervention.",
keywords = "Epithelial to mesenchymal transition (EMT), Linear progression model, Metastasis, Pancreatic cancer, Parallel progression model",
author = "Srustidhar Das and Batra, {Surinder Kumar}",
year = "2015",
month = "1",
day = "1",
doi = "10.2174/1381612821666141211115234",
language = "English (US)",
volume = "21",
pages = "1249--1255",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Pancreatic cancer metastasis

T2 - Are we being pre-EMTed?

AU - Das, Srustidhar

AU - Batra, Surinder Kumar

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pancreatic cancer, often considered a metastatic disease at the time of clinical diagnosis due to lack of any reliable early diagnostic marker(s), is refractory to conventional chemo-and radiotherapy and has a dismal 5-year survival rate of only 6%. Although surgical removal of the primary tumor is considered to be curative, the 5-year survival rate is no more than 20% even in patients with clear resection margins (R0). The recurrence of local and metastatic disease (primarily liver metastasis) post resection is considered to be the leading cause of mortality in these patients. In addition, instances of metastatic disease without any local recurrence post resection have also been observed. Cancer metastasis is the primary cause of mortality in cancer patients and is classically viewed as a late event during the progression of the disease, which is supp orted by the genetic studies used to understand the evolution of pancreatic cancer. However, this view has recently been challenged by studies using mathematical modeling and genetically labeled mouse models of pancreatic cancer to understand the dynamics of tumor cell dissemination and epithelial to mesenchymal transition (EMT) of tumor cells well before the primary tumor is formed. Given that EMT is a hallmark process that initiates the metastatic seeding of cancer cells and the dismal prognosis of pancreatic cancer patients even after efficient removal of the primary tumor (99.9%), an early dissemination hypothesis of cancer cells cannot be undermined. In this review, we will discuss the current views regarding pancreatic cancer metastasis with particular emphasis on the epithelial to mesenchymal transition, its influence on the selection of patients for surgical resection and the therapeutic intervention.

AB - Pancreatic cancer, often considered a metastatic disease at the time of clinical diagnosis due to lack of any reliable early diagnostic marker(s), is refractory to conventional chemo-and radiotherapy and has a dismal 5-year survival rate of only 6%. Although surgical removal of the primary tumor is considered to be curative, the 5-year survival rate is no more than 20% even in patients with clear resection margins (R0). The recurrence of local and metastatic disease (primarily liver metastasis) post resection is considered to be the leading cause of mortality in these patients. In addition, instances of metastatic disease without any local recurrence post resection have also been observed. Cancer metastasis is the primary cause of mortality in cancer patients and is classically viewed as a late event during the progression of the disease, which is supp orted by the genetic studies used to understand the evolution of pancreatic cancer. However, this view has recently been challenged by studies using mathematical modeling and genetically labeled mouse models of pancreatic cancer to understand the dynamics of tumor cell dissemination and epithelial to mesenchymal transition (EMT) of tumor cells well before the primary tumor is formed. Given that EMT is a hallmark process that initiates the metastatic seeding of cancer cells and the dismal prognosis of pancreatic cancer patients even after efficient removal of the primary tumor (99.9%), an early dissemination hypothesis of cancer cells cannot be undermined. In this review, we will discuss the current views regarding pancreatic cancer metastasis with particular emphasis on the epithelial to mesenchymal transition, its influence on the selection of patients for surgical resection and the therapeutic intervention.

KW - Epithelial to mesenchymal transition (EMT)

KW - Linear progression model

KW - Metastasis

KW - Pancreatic cancer

KW - Parallel progression model

UR - http://www.scopus.com/inward/record.url?scp=84926383750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926383750&partnerID=8YFLogxK

U2 - 10.2174/1381612821666141211115234

DO - 10.2174/1381612821666141211115234

M3 - Article

C2 - 25506899

AN - SCOPUS:84926383750

VL - 21

SP - 1249

EP - 1255

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 10

ER -